Pancreatic cancer patients continue to face poor outcomes – partially due to the tissue surrounding the tumor hampering intravenously delivered chemotherapy drug access to the cancer cells.
Intravenous chemotherapy treatment is often associated with debilitating side effects and may be ineffective in treating this type of cancer due to pancreatic tumors lacking blood vessels.
These blood vessels are critical for transporting the administration of chemotherapy to the tumor.
Unlike intravenous chemotherapy, RenovoRx has a unique therapy that delivers intra-arterial chemotherapy targeting pancreatic cancer via an artery close to the tumor.
The TIGeR-PaC study (clinicaltrials.gov/ct2/show/NCT03257033) was set up to determine whether this targeted method of delivering chemotherapy will extend survival while also improving quality of life.
The Phase III study is open to adults recently diagnosed with pancreatic adenocarcinoma that has not spread to other body parts and cannot be treated surgically.
If you or a loved one would like to sign up for the study, register here. Once you do so, a member of the xCures study team will assist you through the screening and enrollment process to determine eligibility.
Even if you are not eligible for the TIGeR-PaC study, xCures will assess your medical records and use their A.I. technology to determine eligibility for other promising trials or treatments.